deltatrials
Completed OBSERVATIONAL NCT01398306

Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours. (BANN)

Sponsor: University Medical Center Groningen

Updated 11 times since 2017 Last updated: May 3, 2024 Started: Jul 31, 2011 Primary completion: Apr 30, 2012 Completion: Apr 30, 2012

This observational or N/A phase trial investigates Carcinoid Tumor and Carcinoma and is currently completed. University Medical Center Groningen leads this study, which shows 11 recorded versions since 2011 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Study Description(click to expand)

* To analyse the concentration catecholamines in thrombocytes of patients with clear cell renal cell carcinoma and low grade neuroendocrine tumours. * To compare these concentrations with the concentrations catecholamines in thrombocytes of healthy controls. * To analyse the concentration catecholamines in thrombocytes of patients with clear cell renal cell carcinoma and patients with low grade neuroendocrine tumours with and without medication.

* To analyse the concentration catecholamines in thrombocytes of patients with clear cell renal cell carcinoma and low grade neuroendocrine tumours. * To compare these concentrations with the concentrations catecholamines in thrombocytes of healthy controls. * To analyse the concentration catecholamines in thrombocytes of patients with clear cell renal cell carcinoma and patients with low grade neuroendocrine tumours with and without medication.

Status Flow

~Jan 2017 – ~Aug 2017 · 7 months · monthly snapshotCompleted~Aug 2017 – ~Apr 2018 · 8 months · monthly snapshotCompleted~Apr 2018 – ~May 2018 · 30 days · monthly snapshotCompleted~May 2018 – ~Jun 2018 · 31 days · monthly snapshotCompleted~Jun 2018 – ~Nov 2020 · 29 months · monthly snapshotCompleted~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshotCompleted~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotCompleted~Dec 2021 – ~Jun 2024 · 30 months · monthly snapshotCompleted~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 19 months · monthly snapshotCompleted

Change History

11 versions recorded
  1. Sep 2024 — Present [monthly]

    Completed

  2. Jul 2024 — Sep 2024 [monthly]

    Completed

  3. Jun 2024 — Jul 2024 [monthly]

    Completed

  4. Dec 2021 — Jun 2024 [monthly]

    Completed

  5. Jan 2021 — Dec 2021 [monthly]

    Completed

Show 6 earlier versions
  1. Nov 2020 — Jan 2021 [monthly]

    Completed

  2. Jun 2018 — Nov 2020 [monthly]

    Completed

  3. May 2018 — Jun 2018 [monthly]

    Completed

  4. Apr 2018 — May 2018 [monthly]

    Completed

    Phase: NANone

  5. Aug 2017 — Apr 2018 [monthly]

    Completed NA

  6. Jan 2017 — Aug 2017 [monthly]

    Completed NA

    First recorded

Jul 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • University Medical Center Groningen
Data source: University Medical Center Groningen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations